Journal Cover
Diabetes Care
Journal Prestige (SJR): 6.693
Citation Impact (citeScore): 8
Number of Followers: 535  
  Full-text available via subscription Subscription journal
ISSN (Print) 0149-5992 - ISSN (Online) 1935-5548
Published by American Diabetes Association Homepage  [4 journals]
  • Diabetes Awareness Among Coronary Artery Disease Patients Is Higher in
           Women Than in Men
    • Authors: Saely; C. H.; Mader, A.; Heinzle, C. F.; Zanolin-Purin, D.; Larcher, B.; Vonbank, A.; Drexel, H.
      PubDate: 2019-05-20T12:00:26-07:00
      DOI: 10.2337/dc19-0241
      Issue No: Vol. 42, No. 6 (2019)
  • Assessing the Association Between Dipeptidyl Peptidase 4 Inhibitor Use and
           Inflammatory Bowel Disease Through Drug Adverse Event Reporting
    • Authors: Wang; T.; Lu, W.; Li, D.; Tang, H.; Yang, J. Y.; Buse, J. B.; Stürmer, T.
      Keywords: Epidemiology-Diabetes Complications
      PubDate: 2019-05-20T12:00:26-07:00
      DOI: 10.2337/dc18-1609
      Issue No: Vol. 42, No. 6 (2019)
  • Glucagon-Like Peptide 1 Receptor Agonists and Risk of Diabetic Retinopathy
           Complications: Cohort Study in Nationwide Registers From Two Countries
    • Authors: Ueda; P.; Pasternak, B.; Eliasson, B.; Svensson, A.-M.; Franzen, S.; Gudbjörnsdottir, S.; Hveem, K.; Jonasson, C.; Melbye, M.; Svanström, H.
      Keywords: Complications-Retinopathy
      PubDate: 2019-05-20T12:00:26-07:00
      DOI: 10.2337/dc18-2532
      Issue No: Vol. 42, No. 6 (2019)
  • Comment on Davis et al. Effects of Severe Hypoglycemia on Cardiovascular
           Outcomes and Death in the Veterans Affairs Diabetes Trial. Diabetes Care
    • Authors: Standl; E.; Green, J. B.; Holman, R. R.; on behalf of the TECOS Study Group
      Keywords: Complications-Hypoglycemia
      PubDate: 2019-05-20T12:00:26-07:00
      DOI: 10.2337/dc18-2597
      Issue No: Vol. 42, No. 6 (2019)
  • Comment on Feig et al. Pumps or Multiple Daily Injections in Pregnancy
           Involving Type 1 Diabetes: A Prespecified Analysis of the CONCEPTT
           Randomized Trial. Diabetes Care 2018;41:2471-2479
    • Authors: Sacha; J. M.; Lane, W. S.
      PubDate: 2019-05-20T12:00:26-07:00
      DOI: 10.2337/dc19-0176
      Issue No: Vol. 42, No. 6 (2019)
  • Response to Comment on Feig et al. Pumps or Multiple Daily Injections in
           Pregnancy Involving Type 1 Diabetes: A Prespecified Analysis of the
           CONCEPTT Randomized Trial. Diabetes Care 2018;41:2471-2479
    • Authors: Feig; D. S.; Corcoy, R.; Donovan, L. E.; Murphy, K. E.; Barrett, J. F. R.; Sanchez, J. J.; Ruedy, K.; Kollman, C.; Tomlinson, G.; Murphy, H. R.; on behalf of the CONCEPTT Collaborative Group
      PubDate: 2019-05-20T12:00:26-07:00
      DOI: 10.2337/dci19-0013
      Issue No: Vol. 42, No. 6 (2019)
  • Comment on Davis et al. Development and Validation of a Simple Hip
           Fracture Risk Prediction Tool for Type 2 Diabetes: The Fremantle Diabetes
           Study Phase I. Diabetes Care 2018;42:102-109
    • Authors: Buzkova; P.; Barzilay, J. I.
      PubDate: 2019-05-20T12:00:26-07:00
      DOI: 10.2337/dc19-0204
      Issue No: Vol. 42, No. 6 (2019)
  • Response to Comment on Davis et al. Development and Validation of a Simple
           Hip Fracture Risk Prediction Tool for Type 2 Diabetes: the Fremantle
           Diabetes Study Phase I. Diabetes Care 2018;42:102-109
    • Authors: Davis; W. A.; Hamilton, E. J.; Bruce, D. G.; Davis, T. M. E.
      PubDate: 2019-05-20T12:00:26-07:00
      DOI: 10.2337/dci19-0015
      Issue No: Vol. 42, No. 6 (2019)
  • Comment on Evron et al. Changes in Screening Practices for Prediabetes and
           Diabetes Since the Recommendation for Hemoglobin A1c Testing. Diabetes
           Care 2019;42:576-584
    • Authors: Stankevich; L.; Galhaud, J.-P.; Kuvshinov, R.; Helmer, C.; Poupon, P.; Blanco, L.; Monlun, M.; Foussard, N.; Mohammedi, K.; Rigalleau, V.
      PubDate: 2019-05-20T12:00:26-07:00
      DOI: 10.2337/dc19-0375
      Issue No: Vol. 42, No. 6 (2019)
  • Response to Comment on Evron et al. Changes in Screening Practices for
           Prediabetes and Diabetes Since the Recommendation for Hemoglobin A1c
           Testing. Diabetes Care 2019;42:576-584
    • Authors: Evron; J. M.; Herman, W. H.; McEwen, L. N.
      PubDate: 2019-05-20T12:00:26-07:00
      DOI: 10.2337/dci19-0016
      Issue No: Vol. 42, No. 6 (2019)
  • Comment on Echouffo-Tcheugui et al. Visit-to-Visit Glycemic Variability
           and Risks of Cardiovascular Events and All-Cause Mortality: The ALLHAT
           Study. Diabetes Care 2019;42:486-493
    • Authors: Monnier; L.; Colette, C.; Owens, D.
      PubDate: 2019-05-20T12:00:26-07:00
      DOI: 10.2337/dc19-0463
      Issue No: Vol. 42, No. 6 (2019)
  • In This Issue of Diabetes Care
    • Pages: 989 - 990
      PubDate: 2019-05-20T12:00:26-07:00
      DOI: 10.2337/dc19-ti06
      Issue No: Vol. 42, No. 6 (2019)
  • SGLT Inhibitors for Type 1 Diabetes: Proceed With Extreme Caution
    • Authors: Wolfsdorf; J. I.; Ratner, R. E.
      Pages: 991 - 993
      Keywords: Clinical Therapeutics/New Technology-Oral Agents
      PubDate: 2019-05-20T12:00:26-07:00
      DOI: 10.2337/dci19-0008
      Issue No: Vol. 42, No. 6 (2019)
  • Diabetes Diagnosis and Control: Missed Opportunities to Improve Health:
           The 2018 Kelly West Award Lecture
    • Authors: Cowie C. C.
      Pages: 994 - 1004
      Abstract: Diabetes is a prevalent condition in the U.S. and worldwide, with expanding impact over time as it affects progressively younger ages as well as older ages as people live longer. Costs of diabetes to those affected and to society as a whole continue to increase. Costs are realized through daily treatment regimens throughout life to control glycemia and other risk factors for complications as diabetes progresses, diabetes complications and disability and their treatments, health care visits and hospitalization, and as indirect costs via lower quality of life and lost productivity. Diagnosing diabetes is key to affording the opportunity to treat diabetes, and diabetes control is key to reducing the risk of complications. Yet the magnitude of undiagnosed diabetes and poor control of diabetes is large. And just as certain subgroups of the population are affected disproportionately by diabetes and diabetes complications, so are they affected disproportionately by undiagnosed diabetes and poor control. This review addresses the epidemiology of undiagnosed diabetes and diabetes control, largely covering their magnitude, demographic variation, trends over time, and predictors. For diabetes control, it focuses on control of A1C, blood pressure, and lipid levels, although there are many other facets of diabetes control and preventive care that also could be examined. The review is based predominantly on data from the National Health and Nutrition Examination Survey (NHANES), a U.S. health survey that includes both an interview and examination component that has been conducted continuously since 1999 and episodically for decades earlier. The interview elicits self-reported health responses pertaining to diabetes and other medical conditions and an examination that measures glycemic indicators, blood pressure, and lipids, which provide much of the material presented herein. Data from other studies are also presented and described.
      Keywords: Epidemiology-Other
      PubDate: 2019-05-20T12:00:26-07:00
      DOI: 10.2337/dci18-0047
      Issue No: Vol. 42, No. 6 (2019)
  • Robert Tattersall, a Diabetes Physician Ahead of His Time
    • Authors: Heller S. R.
      Pages: 1005 - 1008
      Keywords: Epidemiology-Clinical-Diagnosis and Screening
      PubDate: 2019-05-20T12:00:26-07:00
      DOI: 10.2337/dci18-0063
      Issue No: Vol. 42, No. 6 (2019)
  • Efficacy of Fish Oil and/or Probiotic Intervention on the Incidence of
           Gestational Diabetes Mellitus in an At-Risk Group of Overweight and Obese
           Women: A Randomized, Placebo-Controlled, Double-Blind Clinical Trial
    • Authors: Pellonperä; O.; Mokkala, K.; Houttu, N.; Vahlberg, T.; Koivuniemi, E.; Tertti, K.; Rönnemaa, T.; Laitinen, K.
      Pages: 1009 - 1017
      Abstract: OBJECTIVETo assess whether the risk of gestational diabetes mellitus (GDM) may be lowered and glucose metabolism improved by daily administration of fish oil and/or probiotic supplements in overweight and obese pregnant women.RESEARCH DESIGN AND METHODSWe randomized in a double-blind manner 439 women (mean 13.9 ± 2.1 gestational weeks [gw]) into four intervention groups: fish oil + placebo, probiotics + placebo, fish oil + probiotics, and placebo + placebo. Fish oil (1.9 g docosahexaenoic acid and 0.22 g eicosapentaenoic acid) and probiotic supplements (Lactobacillus rhamnosus HN001 and Bifidobacterium animalis ssp. lactis 420, 1010 colony-forming units each) were provided for daily consumption from randomization beyond delivery. Primary outcomes were the incidence of GDM diagnosed with oral glucose tolerance test targeted at 24–28 gw and the change in fasting glucose between randomization and late pregnancy (mean 35.2 ± 0.9 gw). Insulin concentration, insulin resistance HOMA2-IR index, and pregnancy outcomes were determined, as were adverse effects related to the intervention. Analyses were by intent to treat.RESULTSNo differences were found among the intervention groups in the maternal and neonatal pregnancy outcomes or side effects related to the intervention (P> 0.05). The proportion of women with GDM (94 of 377; fish oil + placebo, 23 of 96, 24.0%; probiotics + placebo, 25 of 99, 25.3%; fish oil + probiotics, 26 of 91, 28.6%; and placebo + placebo, 20 of 91, 22.0%) and the change in glucose, insulin, or HOMA2-IR (n = 364) did not differ among the intervention groups (P> 0.11 for all comparisons).CONCLUSIONSAn intervention with fish oil and/or probiotics during pregnancy seemed to be both safe and well tolerated but conferred no benefits in lowering the risk of GDM or improving glucose metabolism in overweight and obese women.
      Keywords: Nutrition-Clinical
      PubDate: 2019-05-20T12:00:26-07:00
      DOI: 10.2337/dc18-2591
      Issue No: Vol. 42, No. 6 (2019)
  • Closing the Gap: Results of the Multicenter Canadian Randomized Controlled
           Trial of Structured Transition in Young Adults With Type 1 Diabetes
    • Authors: Spaic; T.; Robinson, T.; Goldbloom, E.; Gallego, P.; Hramiak, I.; Lawson, M. L.; Malcolm, J.; Mahon, J.; Morrison, D.; Parikh, A.; Simone, A.; Stein, R.; Uvarov, A.; Clarson, C.; for the JDRF Canadian Clinical Trial CCTN1102 Study Group
      Pages: 1018 - 1026
      Abstract: OBJECTIVETo determine if a structured transition program for young adults with type 1 diabetes improves clinic attendance, glycemic control, diabetes-related distress, quality of life, and satisfaction with care.RESEARCH DESIGN AND METHODSIn this multicenter randomized controlled trial, young adults (17–20 years) with type 1 diabetes were randomly assigned to a transition program with a transition coordinator or to standard care. The intervention lasted 18 months (6 in pediatric and 12 in adult care). The primary outcome was the proportion of participants who failed to attend at least one adult diabetes clinic visit during the 12-month follow-up after completion of the intervention.RESULTSWe randomized 205 participants, 104 to the transition program and 101 to standard care. Clinic attendance was improved in the transition program (mean [SD] number of visits 4.1 [1.1] vs. 3.6 [1.2], P = 0.002), and there was greater satisfaction with care (mean [SD] score 29.0 [2.7] vs. 27.9 [3.4], P = 0.032) and less diabetes-related distress (mean [SD] score 1.9 [0.8] vs. 2.1 [0.8], P = 0.049) reported than in standard care. There was a trend toward improvement in mean HbA1c (8.33% [68 mmol/mol] vs. 8.80% [73 mmol/mol], P = 0.057). During the 12-month follow-up, there was no difference in those failing to attend at least one clinic visit (P = 0.846), and the mean change in HbA1c did not differ between the groups (P = 0.073). At completion of follow-up, the groups did not differ with respect to satisfaction with care or diabetes-related distress and quality of life.CONCLUSIONSTransition support during this 18-month intervention was associated with increased clinic attendance, improved satisfaction with care, and decreased diabetes-related distress, but these benefits were not sustained 12 months after completion of the intervention.
      Keywords: Pediatrics-Type 1 Diabetes
      PubDate: 2019-05-20T12:00:26-07:00
      DOI: 10.2337/dc18-2187
      Issue No: Vol. 42, No. 6 (2019)
  • Variation in the Plasma Membrane Monoamine Transporter (PMAT) (Encoded by
           SLC29A4) and Organic Cation Transporter 1 (OCT1) (Encoded by SLC22A1) and
           Gastrointestinal Intolerance to Metformin in Type 2 Diabetes: An IMI
           DIRECT Study
    • Authors: Dawed; A. Y.; Zhou, K.; van Leeuwen, N.; Mahajan, A.; Robertson, N.; Koivula, R.; Elders, P. J. M.; Rauh, S. P.; Jones, A. G.; Holl, R. W.; Stingl, J. C.; Franks, P. W.; McCarthy, M. I.; 't Hart, L. M.; Pearson, E. R.; for the IMI DIRECT Consortium; IMI DIRECT Consortium
      Pages: 1027 - 1033
      Abstract: OBJECTIVEGastrointestinal adverse effects occur in 20–30% of patients with metformin-treated type 2 diabetes, leading to premature discontinuation in 5–10% of the cases. Gastrointestinal intolerance may reflect localized high concentrations of metformin in the gut. We hypothesized that reduced transport of metformin via the plasma membrane monoamine transporter (PMAT) and organic cation transporter 1 (OCT1) could increase the risk of severe gastrointestinal adverse effects.RESEARCH DESIGN AND METHODSThe study included 286 severe metformin-intolerant and 1,128 metformin-tolerant individuals from the IMI DIRECT (Innovative Medicines Initiative: DIabetes REsearCh on patient straTification) consortium. We assessed the association of patient characteristics, concomitant medication, and the burden of mutations in the SLC29A4 and SLC22A1 genes on odds of intolerance.RESULTSWomen (P < 0.001) and older people (P < 0.001) were more likely to develop metformin intolerance. Concomitant use of transporter-inhibiting drugs increased the odds of intolerance (odds ratio [OR] 1.72, P < 0.001). In an adjusted logistic regression model, the G allele at rs3889348 (SLC29A4) was associated with gastrointestinal intolerance (OR 1.34, P = 0.005). rs3889348 is the top cis-expression quantitative trait locus for SLC29A4 in gut tissue where carriers of the G allele had reduced expression. Homozygous carriers of the G allele treated with transporter-inhibiting drugs had more than three times higher odds of intolerance compared with carriers of no G allele and not treated with inhibiting drugs (OR 3.23, P < 0.001). Use of a genetic risk score derived from rs3889348 and SLC22A1 variants found that the odds of intolerance were more than twice as high in individuals who carry three or more risk alleles compared with those carrying none (OR 2.15, P = 0.01).CONCLUSIONSThese results suggest that intestinal metformin transporters and concomitant medications play an important role in the gastrointestinal adverse effects of metformin.
      Keywords: Genetics-Type 2 Diabetes
      PubDate: 2019-05-20T12:00:26-07:00
      DOI: 10.2337/dc18-2182
      Issue No: Vol. 42, No. 6 (2019)
  • Prepregnancy Habitual Intakes of Total, Supplemental, and Food Folate and
           Risk of Gestational Diabetes Mellitus: A Prospective Cohort Study
    • Authors: Li; M.; Li, S.; Chavarro, J. E.; Gaskins, A. J.; Ley, S. H.; Hinkle, S. N.; Wang, X.; Ding, M.; Bell, G.; Bjerregaard, A. A.; Olsen, S. F.; Mills, J. L.; Hu, F. B.; Zhang, C.
      Pages: 1034 - 1041
      Abstract: OBJECTIVETo identify novel modifiable risk factors of gestational diabetes mellitus (GDM) by examining the association between prepregnancy habitual folate intake and GDM risk.RESEARCH DESIGN AND METHODSThe study included 14,553 women in the Nurses’ Health Study II who reported at least one singleton pregnancy between the 1991 and 2001 questionnaires. Prepregnancy intakes of total folate, supplemental folate, and food folate were assessed using a food frequency questionnaire administered every 4 years. Incident GDM was ascertained from a self-reported physician diagnosis. Relative risks (RRs) of GDM were estimated using log-binomial models, with adjustment for demographic, lifestyle, and dietary factors.RESULTSOver the study follow-up, 824 incident GDM cases were reported among 20,199 pregnancies. Women with adequate total folate intake (≥400 μg/day) had an RR of GDM of 0.83 (95% CI 0.72, 0,95, P = 0.007) compared with women with inadequate intake (
      Keywords: Epidemiology-Nutrition
      PubDate: 2019-05-20T12:00:26-07:00
      DOI: 10.2337/dc18-2198
      Issue No: Vol. 42, No. 6 (2019)
  • Diabetes-Related Complications and Mortality in Patients With Young-Onset
           Latent Autoimmune Diabetes: A 14-Year Analysis of the Prospective Hong
           Kong Diabetes Register
    • Authors: Luk; A. O. Y.; Lau, E. S. H.; Lim, C.; Kong, A. P. S.; Chow, E.; Ma, R. C. W.; Chan, J. C. N.
      Pages: 1042 - 1050
      Abstract: OBJECTIVEYoung-onset diabetes is heterogeneous in etiology and disease progression. We compared the incidence of diabetes-related complications and mortality in patients with young-onset type 2 diabetes with or without anti-GAD antibodies and patients with type 1 diabetes. We determined changes in glycemic control before and after commencement of insulin therapy stratified by antibody status.RESEARCH DESIGN AND METHODSBetween 1994 and 2012, 1,504 consecutively enrolled patients with type 2 diabetes who had received a diagnosis at
      Keywords: Epidemiology-Diabetes Complications
      PubDate: 2019-05-20T12:00:26-07:00
      DOI: 10.2337/dc18-1796
      Issue No: Vol. 42, No. 6 (2019)
  • Predicting Islet Cell Autoimmunity and Type 1 Diabetes: An 8-Year TEDDY
           Study Progress Report
    • Authors: Krischer; J. P.; Liu, X.; Vehik, K.; Akolkar, B.; Hagopian, W. A.; Rewers, M. J.; She, J.-X.; Toppari, J.; Ziegler, A.-G.; Lernmark, A.; the TEDDY Study Group; TEDDY Study Group
      Pages: 1051 - 1060
      Abstract: OBJECTIVEAssessment of the predictive power of The Environmental Determinants of Diabetes in the Young (TEDDY)-identified risk factors for islet autoimmunity (IA), the type of autoantibody appearing first, and type 1 diabetes (T1D).RESEARCH DESIGN AND METHODSA total of 7,777 children were followed from birth to a median of 9.1 years of age for the development of islet autoantibodies and progression to T1D. Time-dependent sensitivity, specificity, and receiver operating characteristic (ROC) curves were calculated to provide estimates of their individual and collective ability to predict IA and T1D.RESULTSHLA genotype (DR3/4 vs. others) was the best predictor for IA (Youden’s index J = 0.117) and single nucleotide polymorphism rs2476601, in PTPN22, was the best predictor for insulin autoantibodies (IAA) appearing first (IAA-first) (J = 0.123). For GAD autoantibodies (GADA)-first, weight at 1 year was the best predictor (J = 0.114). In a multivariate model, the area under the ROC curve (AUC) was 0.678 (95% CI 0.655, 0.701), 0.707 (95% CI 0.676, 0.739), and 0.686 (95% CI 0.651, 0.722) for IA, IAA-first, and GADA-first, respectively, at 6 years. The AUC of the prediction model for T1D at 3 years after the appearance of multiple autoantibodies reached 0.706 (95% CI 0.649, 0.762).CONCLUSIONSPrediction modeling statistics are valuable tools, when applied in a time-until-event setting, to evaluate the ability of risk factors to discriminate between those who will and those who will not get disease. Although significantly associated with IA and T1D, the TEDDY risk factors individually contribute little to prediction. However, in combination, these factors increased IA and T1D prediction substantially.
      Keywords: Epidemiology-Type 1 Diabetes
      PubDate: 2019-05-20T12:00:26-07:00
      DOI: 10.2337/dc18-2282
      Issue No: Vol. 42, No. 6 (2019)
  • A Lack of Decline in Major Nontraumatic Amputations in Texas: Contemporary
           Trends, Risk Factor Associations, and Impact of Revascularization
    • Authors: Garcia; M.; Hernandez, B.; Ellington, T. G.; Kapadia, A.; Michalek, J.; Fisher-Hoch, S.; McCormick, J. B.; Prasad, A.
      Pages: 1061 - 1066
      Abstract: OBJECTIVENontraumatic major lower extremity amputations (LEAs) have been reported to be declining nationally; however, trends in Texas have been less well described. We evaluated demographic and clinical risk factors and revascularization associations for LEAs by using inpatient hospital discharge data in Texas from 2005 to 2014.RESEARCH DESIGN AND METHODSInpatient hospital discharge data were obtained from the Texas Center for Health Statistics. Multivariate logistic regression analyses were performed to evaluate clinical, ethnic, and socioeconomic risk factors associated with LEA. The impact of revascularization (surgical and/or endovascular) on LEA was analyzed.RESULTSBetween 2005 and 2014, of 19,939,716 admissions, 46,627 were for nontraumatic major LEAs. Over time, LEAs were constant, and revascularization rates during index admission declined. The majority of LEAs occurred in males and in individuals aged 60–79 years. Risk factors associated with LEA included diabetes, peripheral arterial disease, chronic kidney disease, and male sex (P < 0.001). Insurance status, hyperlipidemia, coronary artery disease, and stroke/transient ischemic attack were associated with lower odds of amputation (P < 0.001). Hispanic (odds ratio [OR] 1.51 [95% CI 1.48, 1.55], P < 0.001) and black (OR 1.97 [95% CI 1.92, 2.02], P < 0.001) ethnicities were associated with a higher risk for amputation when compared with non-Hispanic whites. Revascularization, either surgical or endovascular (OR 0.52 [95% CI 0.5, 0.54], P < 0.001), was also associated with lower odds for amputation.CONCLUSIONSAmputation rates in Texas have remained constant, whereas revascularization rates are declining. A higher risk for LEA was seen in minorities, including Hispanic ethnicity, which is the fastest growing demographic in Texas. Revascularization and having insurance were associated with lower odds for amputation.
      Keywords: Epidemiology-Other
      PubDate: 2019-05-20T12:00:26-07:00
      DOI: 10.2337/dc19-0078
      Issue No: Vol. 42, No. 6 (2019)
  • Efficacy and Safety of Empagliflozin in Renal Transplant Recipients With
           Posttransplant Diabetes Mellitus
    • Authors: Halden; T. A. S.; Kvitne, K. E.; Midtvedt, K.; Rajakumar, L.; Robertsen, I.; Brox, J.; Bollerslev, J.; Hartmann, A.; Asberg, A.; Jenssen, T.
      Pages: 1067 - 1074
      Abstract: OBJECTIVESodium–glucose cotransporter 2 (SGLT2) inhibitors have lately become the recommended treatment in patients with type 2 diabetes and high cardiovascular risk. Patients with posttransplant diabetes mellitus (PTDM) also have high cardiovascular risk. The aim of this study was to investigate the safety and efficacy of empagliflozin in renal transplant recipients with PTDM.RESEARCH DESIGN AND METHODSForty-nine renal transplant recipients were included in an investigator-initiated, single-center, prospective, double-blind study and randomized to receive either 10 mg empagliflozin or placebo once daily for 24 weeks. Patients transplanted>1 year ago, diagnosed with PTDM, with stable renal function (estimated glomerular filtration rate [eGFR]>30 mL/min/1.73 m2), and with stable immunosuppressive therapy were studied.RESULTSForty-four renal transplant recipients (22 empagliflozin/22 placebo, 34 males) completed the study. Median (interquartile range) change in glycated hemoglobin (HbA1c) was significantly reduced with empagliflozin compared with placebo: –0.2% (–0.6, –0.1) (–2.0 mmol/mol [–6.5, –1.0]) vs. 0.1% (–0.1, 0.4) (1.0 mmol/mol [–0.75, 3.8]) (P = 0.025). The magnitude of glucose reduction was dependent on GFR and baseline HbA1c. The treatment also resulted in a significant reduction in body weight of –2.5 kg (–4.0, –0.05) compared with an increase of 1.0 kg (0.0, 2.0) in the placebo group (P = 0.014). There were no significant differences between the groups in adverse events, immunosuppressive drug levels, or eGFR.CONCLUSIONSEmpagliflozin appeared safe and improved glycemic control in renal transplant recipients with PTDM compared with placebo. A concomitant reduction in body weight was seen.
      Keywords: Clinical Therapeutics/New Technology-Oral Agents
      PubDate: 2019-05-20T12:00:26-07:00
      DOI: 10.2337/dc19-0093
      Issue No: Vol. 42, No. 6 (2019)
  • Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid
           Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in
           the EXenatide Study of Cardiovascular Event Lowering (EXSCEL)
    • Authors: Bethel; M. A.; Patel, R. A.; Thompson, V. P.; Merrill, P.; Reed, S. D.; Li, Y.; Ahmadi, S.; Katona, B. G.; Gustavson, S. M.; Ohman, P.; Iqbal, N.; Gagel, R. F.; Hernandez, A. F.; Buse, J. B.; Holman, R. R.; for the EXSCEL Study Group
      Pages: 1075 - 1080
      Abstract: OBJECTIVEIncreases in serum calcitonin, a tumor marker for medullary thyroid carcinoma (MTC), have been associated with glucagon-like peptide 1 receptor agonist use in some preclinical studies. We report calcitonin changes in exenatide-treated and placebo-administered participants and MTC incidence in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) and consider the impact of within-trial calcitonin monitoring.RESEARCH DESIGN AND METHODSEXSCEL participants were randomized 1:1 to once-weekly exenatide 2 mg or placebo. Serum calcitonin was measured at baseline (with trial medication discontinued if>40 ng/L) and annually thereafter (with trial medication discontinued if ≥50 ng/L). Median calcitonin concentrations were calculated at each time point, and thyroid malignancies were collected prospectively. Data regarding follow-up after an elevated calcitonin were collected retrospectively.RESULTSAt baseline, 52 (30 exenatide and 22 placebo) participants had calcitonin>40 ng/L, and during follow-up an additional 23 participants (15 exenatide and 8 placebo) had calcitonin ≥50 ng/L in the intention-to-treat population. Median calcitonin concentrations were similar between treatment groups at baseline with no increase over time. Confirmed MTC occurred in three participants (2 exenatide and 1 placebo), all of whom had significantly elevated baseline calcitonin values (413, 422, and 655 ng/L).CONCLUSIONSDuring a median 3.2 years’ follow-up, no change in serum calcitonin was seen with exenatide therapy. The three confirmed cases of MTC all occurred in participants with markedly elevated baseline calcitonin levels, measured prior to trial medication administration. Regular calcitonin monitoring identified no additional cases of MTC, suggesting no benefit of routine calcitonin monitoring during exenatide treatment.
      Keywords: Clinical Therapeutics/New Technology-Non-Insulin Injectables
      PubDate: 2019-05-20T12:00:26-07:00
      DOI: 10.2337/dc18-2028
      Issue No: Vol. 42, No. 6 (2019)
  • Glucose Variables in Type 1 Diabetes Studies With Dapagliflozin: Pooled
           Analysis of Continuous Glucose Monitoring Data From DEPICT-1 and -2
    • Authors: Mathieu; C.; Dandona, P.; Phillip, M.; Oron, T.; Lind, M.; Hansen, L.; Thoren, F.; Xu, J.; Langkilde, A. M.; on behalf of the DEPICT-1 DEPICT-2 Investigators
      Pages: 1081 - 1087
      Abstract: OBJECTIVEThis pooled analysis assessed continuous glucose monitoring (CGM) in patients with inadequately controlled type 1 diabetes (HbA1c ≥7.7 to ≤11.0% [≥61 to ≤97 mmol/mol]) who received dapagliflozin as an adjunct to adjustable insulin.RESEARCH DESIGN AND METHODSCGM data were pooled from two 24-week, double-blind, randomized, phase 3 studies: Dapagliflozin Evaluation in Patients with Inadequately Controlled Type 1 Diabetes (DEPICT-1 and DEPICT-2). These studies comprised 1,591 patients receiving dapagliflozin 5 mg (n = 530), dapagliflozin 10 mg (n = 529), or placebo (n = 532).RESULTSBaseline characteristics were balanced between treatment groups. Patients receiving dapagliflozin 5 mg or 10 mg both spent more time with blood glucose in the range>3.9 to ≤10.0 mmol/L (>70 to ≤180 mg/dL) over 24 h than those receiving the placebo. The adjusted mean (SE) change from baseline at week 24 was 6.48% (0.60) with dapagliflozin 5 mg, 8.08% (0.60) with dapagliflozin 10 mg, and –2.59% (0.61) with placebo. At week 24, the mean amplitude of glucose excursion over 24 h, mean 24-h glucose values, and postprandial glucose values were also improved in patients receiving dapagliflozin over those receiving placebo. No marked differences were found at week 24 between dapagliflozin 5 or 10 mg and placebo in the percentage of glucose values ≤3.9 mmol/L (≤70 mg/dL) or ≤3.0 mmol/L (≤54 mg/dL) over 24 h, or in nocturnal (0000–0559 h) glucose values ≤3.9 mmol/L (≤70 mg/dL).CONCLUSIONSIn patients with type 1 diabetes, treatment with dapagliflozin over 24 weeks improved time in range, mean glucose, and glycemic variability without increasing the time spent in the range indicating hypoglycemia.
      Keywords: Clinical Therapeutics/New Technology-Oral Agents
      PubDate: 2019-05-20T12:00:26-07:00
      DOI: 10.2337/dc18-1983
      Issue No: Vol. 42, No. 6 (2019)
  • Uric Acid Is an Independent Risk Factor for Decline in Kidney Function,
           Cardiovascular Events, and Mortality in Patients With Type 1 Diabetes
    • Authors: Pilemann-Lyberg; S.; Hansen, T. W.; Tofte, N.; Winther, S. A.; Theilade, S.; Ahluwalia, T. S.; Rossing, P.
      Pages: 1088 - 1094
      Abstract: OBJECTIVEPrevious studies have provided inconclusive results on the role of uric acid (UA) in risk prediction. Here we aimed to improve the power and precision of the predictive value of UA for the risk of decline in kidney function, cardiovascular events (CVEs), and mortality in patients with type 1 diabetes (T1D).RESEARCH DESIGN AND METHODSPlasma UA was measured in 670 patients with T1D and various degrees of albuminuria, ranging from normoalbuminuria to macroalbuminuria. Associations of UA with an estimated glomerular filtration rate (eGFR) decline of ≥30%, CVEs, and mortality were analyzed. The median follow-up time was 5.3 years [interquartile range (IQR) 2.7–6.2 years] for a decline in eGFR of ≥30%, 5.8 years (2.5–6.4 years) for progression in albuminuria status, 5.1 years (4.7–5.6 years) for CVE, and 6.2 years (5.8–6.7 years) for mortality. Both univariable and multivariable associations of UA with relevant outcomes and variables were reported. Hazard ratios (HRs) were calculated per doubling of the UA level.RESULTSA doubling in UA level was associated with a higher risk of decline in eGFR of ≥30% (n = 89) (HR 3.18 [IQR 1.71–5.93]; P < 0.001), CVE (n = 94) (HR 2.25 [IQR 1.20–4.21]; P = 0.011), and mortality (n = 58) (HR 2.58 [IQR 1.12–5.90]; P = 0.025) in adjusted analyses. Adding UA to the adjusted model including conventional risk factors improved the relative integrated discrimination index by 12.6% for a decline in eGFR of ≥30% (P < 0.001), 6.5% for CVE (P = 0.010), and 11.8% (P = 0.003) for mortality. A doubling in UA level was also associated with a steeper decline in eGFR (P < 0.0026) and a steeper increase in urine albumin-to-creatinine ratio (P < 0.0027) in adjusted analysis.CONCLUSIONSIn individuals with T1D, a higher UA level is associated with a higher risk of decline in kidney function, CVE, and mortality, independently of other risk factors. Our results suggest that UA has a promising role in risk stratification among individuals with T1D.
      Keywords: Complications-Nephropathy-Clinical and Translational Research
      PubDate: 2019-05-20T12:00:26-07:00
      DOI: 10.2337/dc18-2173
      Issue No: Vol. 42, No. 6 (2019)
  • Association Between Topical Corticosteroid Use and Type 2 Diabetes in Two
           European Population-Based Adult Cohorts
    • Authors: Andersen; Y. M. F.; Egeberg, A.; Ban, L.; Gran, S.; Williams, H. C.; Francis, N. A.; Knop, F. K.; Gislason, G. H.; Skov, L.; Thyssen, J. P.
      Pages: 1095 - 1103
      Abstract: OBJECTIVETopical corticosteroids (CSs) are commonly used to treat inflammatory skin conditions including eczema and psoriasis. Although topical CS package inserts describe hyperglycemia and glycosuria as adverse drug reactions, it is unclear whether topical CS use in real life is also associated with an increased risk of type 2 diabetes (T2D).RESEARCH DESIGN AND METHODSTwo matched case-control studies and one cohort study were conducted using routinely collected health care data from Denmark and the U.K. A total of 115,218 and 54,944 adults were identified as case subjects with new-onset T2D in the Danish and U.K. case-control study, respectively. For the Danish cohort study, 2,689,473 adults were included. The main exposure was topical CSs, and the outcome was incident T2D.RESULTSTopical CS was significantly associated with T2D in the Danish (adjusted odds ratio [OR] 1.25 [95% CI 1.23–1.28]) and U.K. (adjusted OR 1.27 [95% CI 1.23–1.31]) case-control studies. Individuals who were exposed to topical CSs had significantly increased risk of incident T2D (adjusted hazard ratio 1.27 [95% CI 1.26–1.29]). We observed significant dose-response relationships between T2D and increasing potency of topical CSs in the two Danish studies. The results were consistent across all sensitivity analyses.CONCLUSIONSWe found a positive association between topical CS prescribing and incident T2D in Danish and U.K. adult populations. Clinicians should be cognizant of possible diabetogenic effects of potent topical CSs.
      Keywords: Epidemiology-Other
      PubDate: 2019-05-20T12:00:26-07:00
      DOI: 10.2337/dc18-2158
      Issue No: Vol. 42, No. 6 (2019)
  • Testosterone Therapy in Men With Hypogonadism Prevents Progression From
           Prediabetes to Type 2 Diabetes: Eight-Year Data From a Registry Study
    • Authors: Yassin; A.; Haider, A.; Haider, K. S.; Caliber, M.; Doros, G.; Saad, F.; Garvey, W. T.
      Pages: 1104 - 1111
      Abstract: OBJECTIVEType 2 diabetes (T2D) is a public health threat. Prediabetes represents a window of opportunity for intervention to prevent T2D. Men with T2D and prediabetes often have low testosterone. Since testosterone improves glycemic control in T2D, we investigated whether testosterone therapy (TTh) in men with hypogonadism and prediabetes prevents progression to T2D.RESEARCH DESIGN AND METHODSThree hundred and sixteen men with prediabetes (defined as HbA1c 5.7–6.4%) and total testosterone levels ≤12.1 nmol/L combined with symptoms of hypogonadism were analyzed. Two hundred and twenty-nine men received parenteral testosterone undecanoate (T-group), and 87 men with hypogonadism served as untreated control subjects. Metabolic and anthropometric parameters were measured twice yearly for 8 years.RESULTSHbA1c decreased by 0.39 ± 0.03% (P < 0.0001) in the T-group and increased by 0.63 ± 0.1% (P < 0.0001) in the untreated group. In the T-group, 90% achieved normal glucose regulation (HbA1c 6.5%). TTh was also associated with significant improvements in fasting glucose, triglyceride:HDL ratio, triglyceride-glucose index, lipid accumulation product, total cholesterol, LDL, HDL, non-HDL, triglycerides, and Aging Males’ Symptoms (AMS) scale. Significant deterioration in all these parameters was seen in the untreated group. Mortality was 7.4% in the T-group and 16.1% in the untreated group (P < 0.05). The incidence of nonfatal myocardial infarction was 0.4% in the T-group and 5.7% in the untreated group (P < 0.005).CONCLUSIONSLong-term TTh completely prevents prediabetes progression to T2D in men with hypogonadism and improves glycemia, lipids, and AMS score. TTh holds tremendous potential for the large and growing population of men with prediabetes and hypogonadism.
      Keywords: Clinical Therapeutics/New Technology-Non-Insulin Injectables
      PubDate: 2019-05-20T12:00:26-07:00
      DOI: 10.2337/dc18-2388
      Issue No: Vol. 42, No. 6 (2019)
  • Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular
           Events, Kidney Function Decline, and Mortality in Patients With Type 1
    • Authors: Rotbain Curovic; V.; Theilade, S.; Winther, S. A.; Tofte, N.; Eugen-Olsen, J.; Persson, F.; Hansen, T. W.; Jeppesen, J.; Rossing, P.
      Pages: 1112 - 1119
      Abstract: OBJECTIVESoluble urokinase plasminogen activator receptor (suPAR) is an important inflammatory biomarker implicated in endothelial and podocyte dysfunction. However, suPAR’s predictive qualities for complications in type 1 diabetes have yet to be determined. We investigated the prognostic value of suPAR for the development of cardiovascular events, decline in renal function, and mortality in patients with type 1 diabetes.RESEARCH DESIGN AND METHODSWe included 667 patients with type 1 diabetes with various degrees of albuminuria in a prospective study. End points were cardiovascular events (cardiovascular death, nonfatal acute myocardial infarction, nonfatal stroke, or coronary or peripheral arterial interventions), estimated glomerular filtration rate (eGFR) decline ≥30%, progression from lower to higher albuminuric state, development of end-stage renal disease (ESRD), and mortality. Follow-up was 5.2–6.2 years. Results were adjusted for known risk factors. Hazard ratios (HRs) are presented per doubling of suPAR with 95% CI. Relative integrated discrimination improvement (rIDI) was calculated.RESULTSQuantification of suPAR was available in all participants; median (interquartile range) was 3.4 ng/mL (2.7–4.5). The adjusted HR (95% CI) for cardiovascular events (n = 94), progression in albuminuria (n = 36), eGFR decline (n = 93), ESRD (n = 23), and mortality (n = 58) were 3.13 (1.96–5.45, P < 0.001), 1.27 (0.51–3.19, P = 0.61), 2.93 (1.68–5.11, P < 0.001), 2.82 (0.73–11.9, P = 0.13), and 4.13 (1.96–8.69, P < 0.001), respectively. rIDI was significant for cardiovascular events (22.6%, P < 0.001), eGFR decline (14.4%, P < 0.001), and mortality (23.9%, P < 0.001).CONCLUSIONSIn patients with type 1 diabetes and a broad range of albuminuria, a higher level of suPAR is a significant and independent risk factor for cardiovascular events, decline in eGFR ≥30%, and mortality. In addition, suPAR contributes significantly to discrimination for the end points.
      Keywords: Complications-Macrovascular-Atherosclerotic Cardiovascular Disease and Human Diabetes
      PubDate: 2019-05-20T12:00:26-07:00
      DOI: 10.2337/dc18-1427
      Issue No: Vol. 42, No. 6 (2019)
  • Elevated Serum Uric Acid Is Associated With Greater Risk for Hypertension
           and Diabetic Kidney Diseases in Obese Adolescents With Type 2 Diabetes: An
           Observational Analysis From the Treatment Options for Type 2 Diabetes in
           Adolescents and Youth (TODAY) Study
    • Authors: Bjornstad; P.; Laffel, L.; Lynch, J.; El ghormli, L.; Weinstock, R. S.; Tollefsen, S. E.; Nadeau, K. J.; for the TODAY Study Group
      Pages: 1120 - 1128
      Abstract: OBJECTIVEElevated serum uric acid (SUA) is increasingly recognized as a risk factor for kidney disease in adults with diabetes, but data in youth are limited. We hypothesized that elevated SUA predicts development of elevated urinary albumin excretion (UAE) and hypertension over time in teens with type 2 diabetes (T2D).RESEARCH DESIGN AND METHODSSerum creatinine, cystatin C, SUA, and the urine albumin-to-creatinine ratio (UACR) were assessed in 539 obese youth, ages 12–17 years, with T2D duration
      Keywords: Complications-Nephropathy-Clinical and Translational Research
      PubDate: 2019-05-20T12:00:26-07:00
      DOI: 10.2337/dc18-2147
      Issue No: Vol. 42, No. 6 (2019)
  • Nonadherence to Insulin Therapy Detected by Bluetooth-Enabled Pen Cap Is
           Associated With Poor Glycemic Control
    • Authors: Munshi; M. N.; Slyne, C.; Greenberg, J. M.; Greaves, T.; Lee, A.; Carl, S.; Atakov-Castillo, A.; Toschi, E.
      Pages: 1129 - 1131
      Abstract: OBJECTIVETo objectively evaluate adherence to timing and dosing of insulin by using Bluetooth pen caps and examine factors related to adherence.RESEARCH DESIGN AND METHODSBluetooth-enabled insulin pen caps were used in younger (ages 18–35 years) and older (ages ≥65 years) adults on two or more insulin injections per day.RESULTSWe evaluated 75 participants with diabetes, 42 younger (29 ± 4 years) and 33 older (73 ± 7 years). Nonadherence was found in 24% of bolus (Apidra) doses and 36% of basal (Lantus) doses. We divided participants into tertiles on the basis of overall adherence, with the most adherent tertile having 85% dose adherence compared with 49% in the least adherent tertile (P < 0.001). Participants in the most adherent tertile had better glycemic control than those in the least adherent tertile (7.7 ± 1.1% [61 ± 12 mmol/mol] vs. 8.6 ± 1.5% [70 ± 16.4 mmol/mol], P < 0.03).CONCLUSIONSNonadherence to insulin dosing and timing can be objectively assessed by Bluetooth pen caps and is associated with poor glycemic control.
      Keywords: Clinical Therapeutics/New Technology-Glucose Monitoring and Sensing
      PubDate: 2019-05-20T12:00:26-07:00
      DOI: 10.2337/dc18-1631
      Issue No: Vol. 42, No. 6 (2019)
  • Biochemical Urine Testing of Adherence to Cardiovascular Medications
           Reveals High Rates of Nonadherence in People Attending Their Annual Review
           for Type 2 Diabetes
    • Authors: Patel; P.; Gupta, P.; Burns, A.; Mohamed, A. A.; Cole, R.; Lane, D.; Seidu, S.; Khunti, K.
      Pages: 1132 - 1135
      Abstract: OBJECTIVELiquid chromatography—tandem mass spectrometry (LC-MS/MS) is a new method to objectively and robustly detect nonadherence. We applied this technique to study nonadherence to cardiovascular medications in people with type 2 diabetes (T2DM).RESEARCH DESIGN AND METHODSRoutine urine samples, received at the time of the annual diabetes review from 228 people with T2DM in primary care, were assessed for adherence by LC-MS/MS.RESULTSA total of 28.1% patients (N = 64) were nonadherent to antidiabetic, antihypertensive, and/or lipid-lowering medications. Nonadherence to statins was the highest at 23.7%, and nonadherence to oral hypoglycemic agents was 9.3%. HbA1c, albumin-to-creatinine ratio, and lipid profiles were significantly higher in the patients who were nonadherent compared with those who were adherent to treatment.CONCLUSIONSThis unique study shows that routine urine samples can be used for adherence testing screening by LC-MS/MS and has demonstrated high nonadherence rates especially to statins in people with T2DM. Future intervention studies using LC-MS/MS as a diagnostic/therapeutic tool may help to improve clinical outcomes.
      Keywords: Clinical Therapeutics/New Technology-Oral Agents
      PubDate: 2019-05-20T12:00:26-07:00
      DOI: 10.2337/dc18-1453
      Issue No: Vol. 42, No. 6 (2019)
  • Diabetes Care Editors Expert Forum 2018: Managing Big Data for Diabetes
           Research and Care
    • Authors: Riddle; M. C.; Blonde, L.; Gerstein, H. C.; Gregg, E. W.; Holman, R. R.; Lachin, J. M.; Nichols, G. A.; Turchin, A.; Cefalu, W. T.
      Pages: 1136 - 1146
      Abstract: Technological progress in the past half century has greatly increased our ability to collect, store, and transmit vast quantities of information, giving rise to the term "big data." This term refers to very large data sets that can be analyzed to identify patterns, trends, and associations. In medicine—including diabetes care and research—big data come from three main sources: electronic medical records (EMRs), surveys and registries, and randomized controlled trials (RCTs). These systems have evolved in different ways, each with strengths and limitations. EMRs continuously accumulate information about patients and make it readily accessible but are limited by missing data or data that are not quality assured. Because EMRs vary in structure and management, comparisons of data between health systems may be difficult. Registries and surveys provide data that are consistently collected and representative of broad populations but are limited in scope and may be updated only intermittently. RCT databases excel in the specificity, completeness, and accuracy of their data, but rarely include a fully representative sample of the general population. Also, they are costly to build and seldom maintained after a trial’s end. To consider these issues, and the challenges and opportunities they present, the editors of Diabetes Care convened a group of experts in management of diabetes-related data on 21 June 2018, in conjunction with the American Diabetes Association’s 78th Scientific Sessions in Orlando, FL. This article summarizes the discussion and conclusions of that forum, offering a vision of benefits that might be realized from prospectively designed and unified data-management systems to support the collective needs of clinical, surveillance, and research activities related to diabetes.
      Keywords: Diabetes Education
      PubDate: 2019-05-20T12:00:26-07:00
      DOI: 10.2337/dci19-0020
      Issue No: Vol. 42, No. 6 (2019)
  • International Consensus on Risk Management of Diabetic Ketoacidosis in
           Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter
           (SGLT) Inhibitors
    • Authors: Danne; T.; Garg, S.; Peters, A. L.; Buse, J. B.; Mathieu, C.; Pettus, J. H.; Alexander, C. M.; Battelino, T.; Ampudia-Blasco, F. J.; Bode, B. W.; Cariou, B.; Close, K. L.; Dandona, P.; Dutta, S.; Ferrannini, E.; Fourlanos, S.; Grunberger, G.; Heller, S. R.; Henry, R. R.; Kurian, M. J.; Kushner, J. A.; Oron, T.; Parkin, C. G.; Pieber, T. R.; Rodbard, H. W.; Schatz, D.; Skyler, J. S.; Tamborlane, W. V.; Yokote, K.; Phillip, M.
      Pages: 1147 - 1154
      Abstract: Sodium–glucose cotransporter (SGLT) inhibitors are new oral antidiabetes medications shown to effectively reduce glycated hemoglobin (A1C) and glycemic variability, blood pressure, and body weight without intrinsic properties to cause hypoglycemia in people with type 1 diabetes. However, recent studies, particularly in individuals with type 1 diabetes, have demonstrated increases in the absolute risk of diabetic ketoacidosis (DKA). Some cases presented with near-normal blood glucose levels or mild hyperglycemia, complicating the recognition/diagnosis of DKA and potentially delaying treatment. Several SGLT inhibitors are currently under review by the U.S. Food and Drug Administration and European regulatory agencies as adjuncts to insulin therapy in people with type 1 diabetes. Strategies must be developed and disseminated to the medical community to mitigate the associated DKA risk. This Consensus Report reviews current data regarding SGLT inhibitor use and provides recommendations to enhance the safety of SGLT inhibitors in people with type 1 diabetes.
      Keywords: Clinical Therapeutics/New Technology-Oral Agents
      PubDate: 2019-05-20T12:00:26-07:00
      DOI: 10.2337/dc18-2316
      Issue No: Vol. 42, No. 6 (2019)
  • Erratum. Secular TRends in DiabEtes in India (STRiDE-I): Change in
           Prevalence in Ten Years Among Urban and Rural Populations in Tamil Nadu.
           Diabetes Care 2019;42:476-485
    • Authors: Nanditha; A.; Snehalatha, C.; Satheesh, K.; Susairaj, P.; Simon, M.; Vijaya, L.; Raghavan, A.; Vinitha, R.; Ramachandran, A.
      Pages: 1155 - 1155
      PubDate: 2019-05-20T12:00:26-07:00
      DOI: 10.2337/dc19-er06
      Issue No: Vol. 42, No. 6 (2019)
  • Erratum. Urine Complement Proteins and the Risk of Kidney Disease
           Progression and Mortality in Type 2 Diabetes. Diabetes Care
    • Authors: Vaisar; T.; Durbin-Johnson, B.; Whitlock, K.; Babenko, I.; Mehrotra, R.; Rocke, D. M.; Afkarian, M.
      Pages: 1155 - 1155
      PubDate: 2019-05-20T12:00:26-07:00
      DOI: 10.2337/dc19-er06a
      Issue No: Vol. 42, No. 6 (2019)
  • Issues and Events
    • Pages: 1156 - 1156
      PubDate: 2019-05-20T12:00:26-07:00
      DOI: 10.2337/dc19-ie06
      Issue No: Vol. 42, No. 6 (2019)
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
Home (Search)
Subjects A-Z
Publishers A-Z
Your IP address:
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-